---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-042489"
form_type: "8-K12B"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:45:47.712057+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN

## Summary
- Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.
- Liminatus develops anti-CD47 monoclonal antibody IBA101 for advanced solid cancers including non-small cell lung cancer.
- Leadership: CEO Chris Kim, CFO Scott Dam, CSO Byong C. Yoo.
- Business Combination approved at Iris stockholders meeting on March 4, 2025.
- Advisors: Holland & Knight for Iris, Loeb & Loeb for Liminatus, Raymond James.

## SEC filing metadata
- accession: 0001104659-25-042489
- form_type: 8-K12B
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/0001104659-25-042489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/tm2513514d1_8k12b.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-042489
- JSON: https://secwatch.observer/filing/0001104659-25-042489.json
- Plain text: https://secwatch.observer/filing/0001104659-25-042489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.